Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources

    Research output: Contribution to journalReviewResearchpeer-review

  3. Temporal variation in out-of-hospital cardiac arrest occurrence in individuals with or without diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Incidence of Infective Endocarditis Among Patients With Tetralogy of Fallot

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care.

MATERIALS AND METHODS: All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use.

RESULTS: A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators.

CONCLUSION: The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options.

Original languageEnglish
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue number31
Pages (from-to)3463-3472
Number of pages10
Publication statusPublished - 1 Nov 2021

ID: 68135155